Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of JYB1904 in allergic asthma
CTR20241864Phase 2Completed
- Sponsor
- Jiangsu Jiye Biopharmaceutical
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ozureprubart in allergic asthma, sponsored by Jiangsu Jiye Biopharmaceutical. Started Jun 2024; status: completed.
02
Drugs
ozureprubart
03
Conditions
allergic asthma
Beyond the preview
Go deeper on CTR20241864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241864.